Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | PTGFR | P43088 | 3/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11077553 | 0.94 | CNR2 (0.47) | CNR2ACP3CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL195513 | 0.92 | CNR2 (0.51) | CNR2ACP3GABBR2GABBR1PTGFR | |
| SCHEMBL21632052 | 0.86 | GABBR2 (0.56) | CNR2ACP3GABBR2GABBR1PTGFR | |
| SCHEMBL13703408 | 0.86 | GABBR2 (0.56) | CNR2ACP3GABBR2GABBR1PTGFR | |
| SCHEMBL195741 | 0.84 | CNR2 (0.42) | CNR2ACP3CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL28199545 | 0.81 | CNR2 (0.50) | CNR2ACP3PTGFRCACNA2D1CACNA1B | |
| SCHEMBL27697258 | 0.81 | CNR2 (0.50) | CNR2ACP3PTGFRCACNA2D1CACNA1B | |
| SCHEMBL3179319 | 0.78 | CNR1 (0.48) | CNR2ACP3PTGFRCACNA2D1CACNA1B | |
| SCHEMBL3179325 | 0.78 | CNR1 (0.48) | CNR2ACP3PTGFRCACNA2D1CACNA1B | |
| SCHEMBL3179311 | 0.78 | CNR1 (0.48) | CNR2ACP3PTGFRCACNA2D1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | CNR2 2884/4885ACP3 4278/4885GABBR2 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.